This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Robert Ritch, MD
New York, NY

Theodore Krupin, MD
Chicago, Ill

Charles Henry, MD
Little Rock, Ark

Fred Kurata, MD
Los Angeles, Calif

Arch Ophthalmol. 1995;113(6):699.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In reply

We thank Drs Epstein, Goldbloom, Kramer, and Reines for their interest in our report. We certainly agree that in highrisk patients, psychoactive agents with little or no cholinergic activity should be considered, and we did not mean to imply that the terms "psychoactive" and "anticholinergic" should be equated. However, a high-risk patient is one with an occludable angle, and such a situation is an indication for laser iridotomy.^1,2 After iridotomy, any of these drugs can be given safely (except perhaps in the rare case of complete plateau iris syndrome). Therefore, one need not be concerned about what drugs to prescribe and what drugs not to prescribe. The important point for the psychiatric community is to be able to recognize the high-risk cases, most of which are found in patients with hyperopia.

It should be noted that both fluoxetine hydrochloride and mianserin hydrochloride, a diperazinoazepine antidepressant that has . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?